Abstract: This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligand preferably an antagonist.

Abstract: Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore.

Abstract: The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.

Abstract: The present invention relates to adenosine A-3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Abstract: The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containings them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and (heir salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and (III) and to the preparation thereof.

Abstract: The invention relates to novel processes for the preparation of 5-chloro-4-{3-[N-[2-(3,4-dimethoxyphenyl)-ethyl]-N-methylamino]-propylamino-3(2H) pyridazinone of formula (I) and the pharmaceutically acceptable acid addition salts thereof. An important feature of the invention is using 3,4,5-trichloropyridazone as starting substance of the synthesis.

Abstract: Compounds of general formula (I), wherein R4 and R5 stand for hydrogen atom or form together an 1,3-butadienyl group, optionally substituted by a methylenedioxy group or one or more straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, hydroxy group or halogen atom; are strong adenosine A3 receptor ligands preferably antagonists.

Abstract: A process is disclosed for the preparation of amorphous atorvastatin calcium which comprises dissolving crude atorvastatin calcium in a lower alkanol containing 2 to 4 carbon atoms or a mixture of such alkanols under heating and, after cooling, isolating the precipitated amorphous atorvastatin calcium.

Abstract: The invention relates to a process for the preparation of amorphous atorvastatin calcium by recrystallization of crude atorvastatin from an organic solvent which comprises dissolving crude amorphous atorvastatin calcium in a lower alkanol containing 2-4 carbon atoms or a mixture of such alkanols under heating and isolating the amorphous atorvastatin calcium precipitated after cooling. The atorvastatin calcium obtained is a known valuable agent useful in treating hyperlipidemia and hypercholestrolemia.

Abstract: The disclosure relates to a novel 8-substituted-9H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of formula I and pharmaceutically acceptable quaternary ammonium salts thereof, a process for preparing the same, a pharmaceutical composition containing a 8-substituted-9H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound, and a method of treatment using the pharmaceutical composition. A complete description of the compound of formula I is found in the specification. The compounds of the general formula I possess unique competitive AMPA/kainite antagonist properties making them useful in the treatment of diseases where inhibition of the AMPA/kainite receptors may a favorable effect.

Abstract: A low pressure mercury vapor discharge lamp is provided, said discharge lamp (10) comprising an envelope (12) formed from light-transmitting material and containing an ionizable gas fill (22), mercury, and electrodes (18) sealed in the envelope. The envelope (12) is provided with a single layer coating (14) on the internal surface thereof next to the discharge space. The coating (14) contains halo-phosphate phosphor and 5-30 mass % aluminum oxide relative to the halo-phosphate phosphor, and the primary particle size of the aluminum oxide is smaller than 30 nanometers, the floc size of the aluminum oxide is smaller than 1 micrometer, and the void fraction of the total floc volume is at least 50%.

Abstract: An electrodeless fluorescent reflector lamp includes a housing arrangement having a threaded screw base for receiving line power and a lamp envelope mounted on the housing arrangement. A ballast circuit is disposed within the housing arrangement and is effective for converting line power into an RF signal which excites a fill contained within the lamp envelope to a discharge state thereby resulting in the production of visible light. The lamp envelope is constructed having an upper curved face portion and a lower tapered portion which extends partly within the housing. A reflective coating is applied to the lower tapered portion of the lamp envelope. A phosphor coating distribution is applied to the interior surface of the lamp envelope in a manner so as to maximize the light output from the reflector lamp.

Abstract: A single-ended low pressure mercury vapor discharge lamp including a lamp envelope having at least two tube portions being connected with each other and dosed with additive and gas, and a housing member made in a manner suitable for electrical and mechanical connection to a lamp holder on one end, and mechanically fixing and making electrical contact with the lamp envelope on the other end. The end portion of the tube portions of the lamp envelope which are set at the housing member side are externally coated with a light-reflecting layer.

Abstract: In a luminescent material which comprises a first component for luminescing red light under influence of incident optical radiation and a second component for luminescing in the spectral range from 520 to 560 nm, the second component includes a first phase of garnet crystallization system consisted of yttrium aluminate activated by trivalent cerium and determined by the general structural formula Y.sub.3-a Ce.sub.a Al.sub.5 O.sub.12, wherein 0.0003<a<0.1, and a second phase of hexagonal crystallization system of general structural formula La.sub.b Ce.sub.1-b Al.sub.11 O.sub.18, wherein O<b<1, and the second phase is present in an amount ranging from the amounts detectable by means of X-ray diffractometry to the double amount of the first phase.